Rare disease drug development in the evolving policy environment
An ex-FDA consumer safety officer discussed the challenges of navigating policy and politics in rare diseases at a recent meeting.
Simplifying Clinical Trials
How to increase efficiency and agility in oncology trials
Why going digital is the right step for the pharma industry
How a digital approach to risk management is transforming the pharma industry
How paper protocols may be harming your clinical trial’s success
How digital transformation can bring clinical trials into the 21st century
